EGA
GMAB icon

Eagle Global Advisors’s Genmab GMAB Stock Holding History

Eagle Global Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72M Buy
244,730
+165
+0.1% +$4.38K 0.22% 86
2026
Q1 		$6.56M Sell
244,565
-4,745
-2% -$142K 0.24% 79
2025
Q4 		$7.68M Buy
249,310
+4,840
+2% +$151K 0.28% 72
2025
Q3 		$7.5M Buy
244,470
+34,175
+16% +$833K 0.29% 75
2025
Q2 		$4.34M Buy
210,295
+1,000
+0.5% +$20.5K 0.18% 93
2025
Q1 		$4.1M Buy
+209,295
New +$4.39M 0.17% 96

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eagle Global Advisors's GMAB Position: Q2 2026 in Review

Eagle Global Advisors increased its Genmab (GMAB) stake by 0.07% in Q2 2026, buying an estimated $4.38K and bringing the position to 244,730 shares worth $6.72M. The position accounts for 0.22% of the portfolio, ranked #86.

Eagle Global Advisors first reported a position in GMAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.68M in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Eagle Global Advisors held 244,730 shares of Genmab worth $6.72M as of Q2 2026.
  • Eagle Global Advisors bought 165 Genmab shares in Q2 2026, an estimated $4.38K.
  • Genmab made up 0.22% of Eagle Global Advisors's portfolio in Q2 2026, its #86 holding.
  • Eagle Global Advisors first reported a position in Genmab in Q1 2025 and has held it in 6 quarters since.
  • Eagle Global Advisors's Genmab position peaked at $7.68M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.